.png)
Mid-Size Biopharmaceutical
Outcomes Research, Market Access, Real-World Evidence
Phase III
Oncology
Subscribe to our newsletter to receive the latest case studies.
Mid-Size Biopharmaceutical
Outcomes Research, Market Access, Real-World Evidence
Phase III
Oncology
A mid-size biopharmaceutical company sought to strengthen payer value positioning and define a long-term evidence strategy for a Phase III oncology therapy.
Emerging clinical evidence needed to be translated into differentiated payer value messages, while evidence gaps and future research priorities required validation through stakeholder input.
The client engaged Alkemi to develop an integrated scientific value narrative and evidence generation strategy to support future commercialization and market access planning.
1. Synthesized clinical, economic, and humanistic evidence to establish differentiated payer value messages.
2. Assessed evidence gaps and conducted interviews with six U.S. institutional decision-makers to validate research priorities.
3. Developed a phased U.S. and global evidence generation roadmap aligned with stakeholder needs.
4. Created practical decision-support tools, including a payer value framework and operational cost calculator, to guide future evidence investments.
Align value messaging, evidence generation priorities, and stakeholder insights into a single strategy that supports future market access.
"Alkemi helped us move beyond identifying evidence gaps to building a clear, prioritized evidence strategy we could put into action." - VP, Global Outcomes Research & Real-World Evidence
Established an integrated value strategy that aligned scientific messaging with evidence generation priorities to support future payer and market access planning.
Provided a strategic roadmap to guide future evidence generation and research investments.
Delivered practical decision-support tools that strengthened U.S. and global commercialization planning approximately two years ahead of launch.